explore -WSS

explore

author：comprehensive 2025-09-27 19:38:09 - browse：3468

Cambridge: AbbVie — Ruby Wallau for STAT

AbbVie will pay $10 billion for the biotech firm Immunogen, the company said Thursday, acquiring an approved treatment for ovarian cancer and buying into a burgeoning area of oncology.

Under the agreement, AbbVie will pay $31.26 per share in cash for Immunogen, a nearly 100% premium to the company’s recent trading price. Central to the deal, expected to close in the middle of next year, is Elahere, an Immunogen product that won Food and Drug Administration approval for advanced ovarian cancer in 2022.

Elahere is among a surging class of cancer medicines called antibody-drug conjugates, or ADCs, which are designed to deliver a targeted dose of chemotherapy directly to tumor cells while sparing healthy tissues. AbbVie’s acquisition is the latest multibillion-dollar deal in the space, following Merck’s $22 billion agreement with ADC specialist Daiichi Sankyo and Pfizer’s $43 billion buyout of Seagen earlier this year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： YouTube cracks down on misinformation on cancer treatment

entertainment

WSS

MORE: Michael J. Fox celebrates 62nd birthday: See the loving wishes from his wife Tracy and more

Judge sides with young activists in first

Generate Biomedicines machine learning biotech raises $273M

New weight loss drugs vying to be the next Wegovy or Mounjaro

What to know about the judge who will handle the Trump case

Indictment alleges Trump's ex

knowledge

explore

hotspot

Dobbs anniversary: the lost opportunity of abortion as health care

Private equity could exacerbate cardiology's overuse problem, experts fear

In Memoriam: Notable people who died in 2023

Montana youths win climate lawsuit against state for promoting fossil fuels

Bright Health sells Medicare Advantage business to Molina

Diverse clinical trials: Why aren’t we there yet?

After affirmative action ruling, medical educators look to 'holistic review'

Will the IRA bring competition to the biologics market?

Guidelines to prevent youth baseball injuries need more muscle

IRA could hurt research into orphan drugs for rare diseases

leisure time

Indictment alleges Trump's ex

Telehealth for opioid use disorder is lifesaving

Idaho college killings prosecutors challenge defense's grand jury claims

Idaho college killings prosecutors challenge defense's grand jury claims

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

FDA approves updated Covid vaccines

entertainment

hotspot

entertainment

entertainment